zomacton 1,3 trockensubstanz und lösungsmittel
eurimpharm arzneimittel gmbh - somatropin - trockensubstanz und lösungsmittel - somatropin 1.62mg
zomacton 4 (1,3 mg) trockensubstanz und lösungsmittel
mpa pharma gmbh - somatropin - trockensubstanz und lösungsmittel - somatropin 1.62mg
zomacton 1,3mg trockensubstanz und lösungsmittel
ferring gmbh - somatropin - trockensubstanz und lösungsmittel - somatropin 1.8mg
zomacton 18 (6mg) trockensubstanz und lösungsmittel
ferring gmbh - somatropin - trockensubstanz und lösungsmittel - somatropin 7.mg
genta 100 mg/ml
cp-pharma handelsgesellschaft mbh (3180103) - gentamicinsulfat - injektionslösung - gentamicinsulfat (03989) 170 milligramm - katze; schwein; rind; hund; pferd
erythrocin vet. 200mg/ml
ceva tiergesundheit gmbh (3123507) - erythromycin - injektionslösung - erythromycin (03791) 200 milligramm - schaf; ferkel; schwein; schaf, lamm; rind; kalb, noch nicht wiederkäuend
tremfya
janssen-cilag international nv - guselkumab - psoriasis - immunsuppressiva - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
oxaliplatin ebewe 5 mg/ml pulver zur herstellung einer infusionslösung
ebewe pharma ges.m.b.h. nfg.kg - oxaliplatin - oxaliplatin
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukämie, haarige zelle - antineoplastische mittel - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
rybrevant
janssen-cilag international n.v. - amivantamab - karzinom, nicht kleinzellige lunge - antineoplastische mittel - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.